Skip to main content
Journal cover image

Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity.

Publication ,  Journal Article
Kolotkin, RL; Gabriel Smolarz, B; Meincke, HH; Fujioka, K
Published in: Clin Obes
February 2018

Previously in the SCALE Obesity and Prediabetes trial, at 1 year, participants with obesity (or overweight with comorbidities) and prediabetes receiving liraglutide 3.0 mg experienced greater improvements in health-related quality of life (HRQoL) than those receiving placebo. The current study extends these findings by examining 3-year changes in HRQoL. HRQoL was assessed using the obesity-specific Impact of Weight on Quality of Life-Lite (IWQOL-Lite) questionnaire, as well as the Short-Form 36 v2 (SF-36) health survey. At 3 years, mean change (±standard deviation) in IWQOL-Lite total score from baseline for liraglutide (n = 1472) was 11.0 ± 14.2, vs. 8.1 ± 14.7 for placebo (n = 738) (estimated treatment difference [ETD] 3.4 [95% confidence interval (CI): 2.0, 4.7], P < 0.0001). Mean change in SF-36 physical component summary (PCS) score from baseline for liraglutide was 3.1 ± 7.3, vs. 2.6 ± 7.6 for placebo (ETD 0.87 [95% CI: 0.17, 1.6], P = 0.0156). Mean change in SF-36 mental component summary score did not significantly differ between groups. Both IWQOL-Lite total score and PCS score demonstrated an association between greater HRQoL improvement with higher weight loss. Liraglutide 3.0 mg was also associated with improved health utility (Short-Form-6D and EuroQol-5D, mapped from IWQOL-Lite and/or SF-36) vs. placebo. Liraglutide 3.0 mg, plus diet and exercise, is associated with long-term improvements in HRQoL with obesity or overweight with comorbidity vs. placebo.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Obes

DOI

EISSN

1758-8111

Publication Date

February 2018

Volume

8

Issue

1

Start / End Page

1 / 10

Location

England

Related Subject Headings

  • Young Adult
  • Weight Loss
  • Treatment Outcome
  • Time Factors
  • Surveys and Questionnaires
  • Quality of Life
  • Obesity
  • Middle Aged
  • Mental Health
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kolotkin, R. L., Gabriel Smolarz, B., Meincke, H. H., & Fujioka, K. (2018). Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity. Clin Obes, 8(1), 1–10. https://doi.org/10.1111/cob.12226
Kolotkin, R. L., B. Gabriel Smolarz, H. H. Meincke, and K. Fujioka. “Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity.Clin Obes 8, no. 1 (February 2018): 1–10. https://doi.org/10.1111/cob.12226.
Kolotkin, R. L., et al. “Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity.Clin Obes, vol. 8, no. 1, Feb. 2018, pp. 1–10. Pubmed, doi:10.1111/cob.12226.
Journal cover image

Published In

Clin Obes

DOI

EISSN

1758-8111

Publication Date

February 2018

Volume

8

Issue

1

Start / End Page

1 / 10

Location

England

Related Subject Headings

  • Young Adult
  • Weight Loss
  • Treatment Outcome
  • Time Factors
  • Surveys and Questionnaires
  • Quality of Life
  • Obesity
  • Middle Aged
  • Mental Health
  • Male